Latest News

Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry; Director of the Yale Depression Research Program; and Co-Director of the Yale New Haven Hospital Interventional Psychiatry Service is featured in a NBC Nightly News report about the drug esketamine.

Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, offers perspective in a New York Times report on the use of the drug ketamine to treat patients with depression.

Yale researchers, including first author Samuel Wilkinson, MD, Assistant Professor of Psychiatry, describe in a paper published in Biological Psychiatry their experience providing ketamine as a clinical treatment to participants with severe and treatment-resistant mood disorders.

Building on years of research into its use as a treatment for depression, Yale researchers are now investigating whether ketamine may help veterans suffering from severe post-traumatic stress disorder.

Gerard Sanacora, MD, PhD, George D. Gross and Esther S. Gross Professor of Psychiatry, spoke to Psychiatric News about the effectiveness of NMDA-targeting antidepressants.

The Brain & Behavior Research Foundation has named studies by three Yale School of Medicine faculty in its annual top 10 list of research advancements and breakthroughs in 2017.

Gerard Sanacora, MD, PhD, Professor of Psychiatry and Director of the Yale Depression Research Program, was interviewed for a CBS This Morning report on the use of ketamine to treat depression.

Gerard Sanacora of Yale Psychology tells Time that ketamine is an "exciting" treatment for depression, but further research is needed.

NPR's news program All Things Considered spoke to Gerard Sanacora, MD, PhD, Professor of Psychiatry and Director of the Yale Depression Research Program about the use of the drug ketamine to treat depression.